Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction
|
|
- Emerald Davidson
- 5 years ago
- Views:
Transcription
1 (2000) 12, Suppl 1, S75±S80 ß 2000 Macmillan Publishers Ltd All rights reserved /00 $ Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction 1 1 Department of Urology, Boston University School of Medicine, Boston, MA, USA Phentolamine mesylate is an alpha-1 and alpha-2 selective adrenergic receptor antagonist which has undergone clinical trials for erectile dysfunction treatment. Biochemical and physiological studies in human erectile tissue have revealed a high af nity of phentolamine for alpha-1 and alpha-2 adrenergic receptors. Based on pharmacokinetic studies, it is suggested that 30±40 min following oral ingestion of 40 or 80 mg of phentolamine (Vasomax), the mean plasma phentolamine concentrations are suf cient to occupy the alpha-1 and -2 adrenergic receptors in erectile tissue and thereby result in inhibition of adrenergic-mediated physiologic activity. In large multi-center, placebo-controlled pivotal phase III clinical trials, the mean change in the erectile function domain of the International Index of Erectile Function scores (Questions 1±5 and 15) from screening to the end of treatment was signi cantly higher following use of active drug (40 mg and 80 mg) compared to placebo. Three to four times as many patients receiving phentolamine reported being satis ed or very satis ed compared with those receiving placebo. At doses of 40 mg and 80 mg respectively, 55% and 59% of men were able to achieve vaginal penetration with 51% and 53% achieving penetration on 75% of attempts. The correction of erectile dysfunction or improvement to a less severe category of dysfunction was experienced by 53% of men with the 80 mg dose and 40% with the 40 mg dose of phentolamine. All trends of response were the same regardless of any concomitant medication. There were no severe adverse events. At 40 mg, 7.7% experienced rhinitis and fewer than 3.1% experienced any other side effect of treatment. Phentolamine is safe, well tolerated and ef cacious for the treatment of erectile dysfunction. (2000) 12, Suppl 1, S75±S80 Keywords: penile erection; alpha blocker; oral agents; erectile dysfunction Role of adrenergic agonists Detumescence of the erect penis is initiated by adrenergic agonist stimulation. Adrenergic stimulation results in contraction of the cavernosal arteries with reduced cavernosal arterial in ow as well as contraction of the trabecular smooth muscle leading to collapse of the lacunar spaces. The resultant loss of corporal veno-occlusive function leads to detumescence. The role of the adrenergic neuroeffector system as a mediator of detumescence is noncontroversial. Intracavernosal administration of adrenergic agonists initiate detumescence and have become a routine treatment for prolonged erection. 2 There are several adrenergic agonists with varying af nities for the alpha adrenergic receptors. Correspondence:, 720 Harrison Ave, Boston, MA Received 1 October 1999; accepted 23 ovember 1999 orepinephrine is the physiologic autonomic neurotransmitter and binds both to alpha-1 and alpha-2 adrenergic receptors (Figure 1). Oxymetazoline is another alpha-1 and alpha-2 receptor agonist. Methoxamine, on the other hand, binds primarily to alpha-1 adrenergic receptors while the compound UK-14,304 binds primarily to alpha-2 adrenergic receptors. There are several physiologic activities associated with norepinephrine or catecholamine release at the adrenergic synapse. Sexual intercourse and orgasm is associated with increased heart rate and systolic blood pressure secondary to catecholamine release (Figure 2). 3 Psychologic-mediated release of catecholamines may occur following stressful situations associated with sexual activity such as fear of failure, performance anxiety, anger, shame and embarrassment. Physiologic and=or psychologicmediated catecholamine release may occur secondary to pain associated with Peyronie's disease, prostatitis, epididymitis, or non-genital pain such as headache. All of these above conditions, from
2 76 H 2 Chemical Formulas of orepinephrine and Phentolamine CH orepinephrine CH 3 Phentolamine treatment of erectile dysfunction are as follows. Adrenergic blockade might delay detumescence of the penile erection. Adrenergic blockade might prolong the duration of the erection initiated by sexual stimulation. Adrenergic blockade might potentiate the stimulatory effect of smooth muscle relaxation by removing inhibitory responses mediated by catecholamine release by the sympathetic nervous system. Further research in the effect of alpha adrenergic blockade on the erectile response is needed. Figure 1 Schematic chemical formulas of norepinephrine and phentolamine. sexual intercourse to stress to pain are associated with catecholamine release and an erectolytic effect on penile erection. Principles of adrenergic blockade in the treatment of erectile dysfunction Since activation of adrenergic agonists initiates detumescence, antagonizing the alpha adrenergic contractile response may facilitate the erectile response in men with erectile dysfunction. The principles of adrenergic blockade utilization in the Phentolamine Ð an alpha-1 and alpha-2 adrenergic antagonist Phentolamine mesylate is an alpha-1 and alpha-2 adrenergic antagonist 4±6 which is currently being investigated for its safety and ef cacy as an oral agent in the treatment of male erectile dysfunction. Pharmacokinetics Pharmacokinetic studies in normal volunteers have revealed that the mean phentolamine plasma concentration 30 min after oral ingestion of 40 mg Catecholamine Loading During Sexual Performance mmhg mmhg 125 Blood pressure mmhg 115 beats/min mmhg 85 beats/min 75 mmhg Heart rate 55 beats/min Desire Arousal Orgasm Catecholamine release - causes penile smoothmuscle to contract L. Messenger Sexual Response Cycle Figure 2 Hypothetical release of catecholamine associated with sexual performance from desire to arousal to orgasm. Coital-mediated increases in catecholamine result in an approximate doubling of the resting pulse and a 50% increase in resting systolic blood pressure. Catecholamine release during sexual activity may explain early loss of erection (failure to maintain erectile dysfunction) in some men.
3 phentolamine (Vasomax) tablets was 16±22 ng=ml (42± 50 nm) and after 80 mg was 36±44 ng=ml (80± 100 nm). In 32 individuals, the area under curve (AUC), C max, T max and half-life values for 40 mg and 80 mg phentolamine (Vasomax) tablets were and ngh=ml; and ng=ml; and h; and h, respectively (Figure 3). Plasma phentolamine concentration (ng/ml) Days 1,7,14 (pooled) - 40 mg dose Days 1,7,14 (pooled) - 80 mg dose Time (hours) Figure 3 Pharmacokinetic pro le of phentolamine. Phentolamine represents an agent that has fast onset of therapeutic blood levels (approximately 30±40 min) and fast metabolism (half-life approximately 2 h). Molecular mechanisms The mechanism of action of phentolamine in regulating corpus cavernosum smooth muscle tone has been postulated to be via alpha adrenergic receptor blockade (Figure 4). Detailed biochemical and physiological studies of the mechanism of action of phentolamine mesylate in human corpus cavernosum tissue have recently been reported. 4 Phentolamine mesylate was found to be an effective alpha-1 and alpha-2 adrenergic receptor blocker in corpus cavernosum erectile tissue. Phentolamine competitively displaced speci c alpha-1 receptor ligands (HEAT and prazosin) and speci c alpha-2 receptor ligands (rauwolscine and RX ). The af nity of phentolamine for alpha-1 adrenergic receptors was comparable to the alpha-1a selective receptor antagonist 5-methylurapidil but was less than that of prazosin. The af nity of phentolamine for the alpha-2 adrenergic receptors was greater than that of the alpha-2 receptor agonist UK-14,304 and norepinephrine but was less than that of the alpha-2 receptor antagonists delequamine (RS ) and 77 Phentolamine is an α-selective Receptor Antagonist orepinephrine Phentolamine CH 3 H 2 CH receptor Extracellular Cell membrane α γ Intracellular Gq/11 protein X orepinephrine unable to bind receptor α γ Gq/11 protein Extracellular receptor activated γ α Gq/11 protein activated Cell membrane Intracellular L. Messenger receptor not activated α γ Gq/11 protein not activated Figure 4 Schematic representatation of the mechanism of alpha blockade by phentolamine. The left-hand side of the gure reveals that the sympathetic neurotransmitter alpha-agonist norepinephrine binds to the cell membrane alpha-1 adrenergic receptor initiating receptor conformational changes and activating Gq=11 protein (a critical step to initiate increased intracellular calcium concentration and smooth muscle contraction). The right-hand side of the gure reveals that in the presence of phentolamine, which has high af nity for the alpha receptor, norepinephrine can no longer bind to the oocupied alpha receptor. Since phentolamine binding to the alpha receptor does not induce conformational changes in the receptor, there is no activation of the Gq=11 protein.
4 78 rauwolscine. The relatively high af nity of phentolamine mesylate for alpha-1 and -2 adrenergic receptors suggests that 30±40 min following oral ingestion of 40 mg of phentolamine (Vasomax), the mean plasma phentolamine concentrations (40± 50 nm) are suf cient to occupy the alpha adrenergic receptors in corpus cavernosum erectile tissue and thereby result in inhibition of adrenergic-mediated physiologic activity 4 In corpus cavernosum erectile tissue, phentolamine mesylate shifted the dose response of phenylephrine (selective alpha-1 mediated) and UK14,304 (selective alpha-2 mediated) contraction in a concentration-dependent manner. Phentolamine mesylate also induced concentration dependent relaxation in erectile tissue pre-contracted with the selective alpha-1 receptor agonists phenylephrine and oxymetazoline, the selective alpha-2 receptor agonist UK14,304 and the non-selective agonist norepinephrine. These data indicate that phentolamine alpha-adrenergic binding activity mediates the physiologic inhibition of adrenergic induced corpus cavernosum contractile tone and the resulting relaxation response. 4 Contractile responses by 80 mm KCl and endothelin are mediated by nonadrenergic mechanisms. Those mediated by KCl are thought to occur by electromechanical coupling via depolarization of the corpus cavernosum smooth muscle primarily by activation of L-type calcium channels and calcium in ux. Those mediated by endothelin are thought to occur via receptor mediated intracellular calcium release. Phentolamine mesylate, however, induced relaxation of corpus cavernosum strips pre-contracted with 80 mm KCl or endothelin. Such data suggest that phentolamine mediates corpus cavernosum tissue contractility by both adrenergic and non-adrenergic pathways. This relaxation response was attenuated by the competitive nitric oxide synthase inhibitor L-nitroarginine and by the mechanical disruption of the endothelium. One likely possibility to explain phentolamine mesylate-induced relaxation of KCl contracted tissue was an additional non-adrenergic, endothelial-based, nitricoxide mechanism. 4 Indirect antagonism is a recognized complementary pharmacologic mechanism of action of many natural and synthetic agonists and antagonists. Phentolamine mesylate is an adrenergic antagonist to the contractile substance norepinephrine. Phentolamine was found to also possess the agonist function of tissue relaxation via endothelial nitric oxide pathways. In erectile tissue, phentolamine thus was found to elicit activity via a dual mechanism of action. One pathway was by direct antagonism of alpha-1 and -2 receptors agonists, at the receptor level, resulting in reduced intracellular calcium release and inhibition of contractility. The other mechanism was probably by an indirect, functional antagonism, in which phentolamine enhancer nitric oxide ef ciency in relaxing trabecular smooth muscle. This additional pathway was found to result in increased intracellular cyclic nucleotide levels, augmenting reduced intracellular calcium release and corporal smooth muscle relaxation. 4 Clinical Trials The ef cacy and safety of oral phentolamine (40 mg or 80 mg) was examined for the treatment of mild to moderate erectile dysfunction. 5,6 The patient inclusion criteria included a 6 month history of: (1) a consistent change in the quality of erection that adversely affected patient satisfaction with sexual intercourse; (2) reduced but not absent incidence of awakening with a full erection; (3) dif culty achieving an erection prior to intercourse; (4) dif culty maintaining an erection during intercourse; and (5) neutral to extreme dissatisfaction with the current level of sexual function. At visit 1 (screening) patients were instructed to attempt intercourse four times over four weeks and record results on `Sexual Encounter Pro le' cards. A Sexual Encounter Pro le score of 8±16 meant inclusion into the study. Less than 8 or more than 16 meant exclusion from the study. At visit 2 (baseline), the International Index of Erectile Function was administered. A total of 459 patients were randomized into placebo, phentolamine 40 mg or 80 mg. Patients were again instructed to attempt intercourse four times over four weeks and record results on `Sexual Encounter Pro le' cards. A total of 424 patients completed the study. At visit 3 (end of treatment), the International Index of Erectile Function was again administered. A total of 139, 139 and 146 patients completed placebo, 40 mg and 80 mg oral phentolamine, respectively. The mean age was 57.7, 58.9 and 58.4 y, respectively. The mean height was 69.9, 70.5 and 70.0 inches, respectively. The mean weight was 198.3, and pounds, respectively. The primary ef cacy criteria were the results of the erection domain of the International Index of Erectile Function scores (Questions 1±5 and 15) from screening to the end of treatment and from baseline to the end of treatment. The mean change in the erectile function domain of the International Index of Erectile Function scores (Questions 1±5 and 15) from screening to the end of treatment was: , 2.15 (P < ) and 3.63 (P < ) for placebo, 40 mg and 80 mg, respectively. The mean change in the erectile function domain of the International Index of Erectile Function scores (Questions 1±5 and 15) from baseline to the end of treatment was: 72.3, 5.65 and 6.66 for placebo, 40 mg and 80 mg, respectively. Improvement in erectile function domain scores for placebo, 40 mg
5 and 80 mg were noted in 28%, 53% and 63% of patients, respectively. Additional primary ef cacy criteria included the ability to achieve vaginal penetration and the ability to maintain erection after penetration and achieve ejaculation in at least 75% of attempts. A total of 38%, 51% (P ˆ 0.012) and 53% (P ˆ 0.005) of patients on placebo, 40 mg and 80 mg, respectively, reported the ability to achieve vaginal penetration. The secondary ef cacy criteria were the results of other domain scores of the International Index of Erectile Function scores concerning orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction. Concerning orgasmic function, the mean change from baseline (visit 2) to end of treatment (visit 3) was: , 0.78 (P ˆ ), 1.05 (P < ) for placebo, 40 mg and 80 mg, respectively. Concerning sexual desire, the mean change from baseline (visit 2) to end of treatment (visit 3) was: 0.05, 0.32 (S), 0.18 (S) for placebo, 40 mg and 80 mg, respectively. Concerning intercourse satisfaction, the mean change from baseline (visit 2) to end of treatment (visit 3) was: 0.23, 0.8 (P ˆ ), 1.1 (P < ) for placebo, 40 mg and 80 mg, respectively. Concerning overall satisfaction, the mean change from baseline (visit 2) to end of treatment (visit 3) was: 7 0.2, 1.3 (P ˆ ), 1.35 (P < ) for placebo, 40 mg and 80 mg, respectively. Other secondary ef cacy criteria were the results of questions 3 and 4 of the erectile function domain concerning frequency of penetration and frequency of maintaining an erection. Concerning frequency of penetration, the mean change from baseline (visit 2) to end of treatment (visit 3) was: , 0.3 (P ˆ ), 0.6 P < ) for placebo, 40 mg and 80 mg, respectively. Concerning frequency of penetration, the mean change from baseline (visit 2) to end of treatment (visit 3) was: , 0.3 (P ˆ ), 0.6 (P < ) for placebo, 40 mg and 80 mg, respectively. Concerning frequency of maintaining erection, the mean change from baseline (visit 2) to end of treatment (visit 3) was: 7 0.1, 0.5 (P ˆ ), 0.8 (P < ) for placebo, 40 mg and 80 mg, respectively. Other secondary ef cacy criteria were the results of overall satisfaction with treatment. The proportion of patients satis ed or very satis ed with the study medication was 10%, 33% and 40% for placebo, 40 mg and 80 mg, respectively. Additional secondary ef cacy criteria were the results of shifts in clinical dysfunction for the erectile function domain score on IIEF at baseline (visit 2) and following end of treatment (visit 3). At baseline, 0± 6 points was considered severe dysfunction, 7±12 was considered moderate-severe dysfunction, 13±18 was considered moderate dysfunction, 19±24 was considered mild dysfunction, and 25±30 was con- 79 Map of Pharmacological First-line Therapies Satisfaction city Town of desire Dysfunction detour Function freeway PDE type 5 inhibitor parkway Choice terrace α blocker boulevard Combination st. Central activator avenue Potency place Topical turnpike L. Messenger Figure 5 Cartoon depiction of potential future options for pharmacologic management of men with erectile dysfunction.
6 80 sidered normal function. At the end of treatment, the percent of patients categorically improved was 15%, 40% (P ˆ 0.001) and 53% (P ˆ 0.001) for placebo, 40 mg and 80 mg, respectively. Concerning side effects, the proportion of patients reporting treatment-related adverse events during the study period was as follows. A total of 3.8%, 7.7% and 20.9% reported rhinitis for placebo, 40 mg and 80 mg, respectively. A total of 1.7%, 3.1% and 4.5% reported headache for placebo, 40 mg and 80 mg, respectively. A total of 0.2%, 2.0% and 7.0% reported dizziness for placebo, 40 mg and 80 mg, respectively. A total of 0.6%, 1.5% and 7.0% reported tachycardia for placebo, 40 mg and 80 mg, respectively. A total of 0%, 0.7% and 3.5% reported nausea for placebo, 40 mg and 80 mg, respectively. A total of 0%, 0.2% and 2.0% reported hypotension for placebo, 40 mg and 80 mg, respectively. A total of 0.2%, 0% and 2.0% reported hypertension for placebo, 40 mg and 80 mg, respectively. In conclusion, oral administration of phentolamine in doses of 40 mg and 80 mg has been shown to be effective in enhancing erectile function in men with mild to moderate erectile dysfunction. Phentolamine has been found to signi cantly improve the various domains of the International Index of Erectile Function compared to placebo in terms of erectile function, orgasmic function, intercourse satisfaction and overall satisfaction. Three to four times as many patients receiving phentolamine reported being satis ed or very satis ed with study medication compared with those receiving placebo. Partner satisfaction correlated with patient satisfaction which was statistically signi cant. At doses of 40 mg and 80 mg respectively, 55% and 59% of men were able to achieve vaginal penetration with 51% and 53% achieving penetration on 75% of attempts. The correction of erectile dysfunction or improvement to a less severe category of dysfunction was experienced by 53% of men with the 80 mg dose and 40% with the 40 mg dose of phentolamine. All trends of response were the same regardless of any concomitant medication. Phentolamine is a safe and well-tolerated with an adverse event pro le consistent with its vasorelaxant properties. There were no severe adverse events including no major systemic cardiovascular hemodynamic changes over the therapeutic dose range. There is no evidence of dyspepsia and visual disturbances associated with sildena l. 7 At 40 mg, 7.7% experienced rhinitis and fewer than 3.1% experienced any other side effect of treatment. In the step-care management of men with erectile dysfunction, there will likely be several choices of pharmacological rst-line therapy for the management of erectile dysfunction (Figure 5). The mechanism of erectogenic drugs will vary. One class, already FDA-approved for the safe and effective treatment of erectile dysfunction, acts by inhibition of the phosphodiesterase type 5 enzyme. Phentolamine is an example of a drug class that facilitates erections by alpha-1 and alpha-2 adrenergic blockade. 1 Another class of agents activates central mechanisms involved in penile erection. 8 Another class will utilize prostaglandin E1 administered via topical administration. 9 It is likely that phentolamine mesylate will achieve widespread use as an oral alpha-1 and alpha-2 blocking agent for the treatment of erectile dysfunction. References 1 Lue TF, Tanagho EA. Physiology of erection and pharmacologic management of impotence. J Urol 1987; 137: 829± Brindley GS Cavernosal alpha-blockade: A new technique for investigating and treating erectile impotence. Br J Psychiatry 1983; 143: 332± Muller J. JAMA 1996; 275: 1405± Traish A, Gupta S, Gallant C, Huang YH, Goldstein, I. Phentolamine mesylate relaxes penile corpus cavernosum tissue by adrenergic and non-adrenergic mechanisms. Int J Imp Res 1998; 10: 215± Goldstein I, the Vasomax Study Group: Update of Safety and Ef cacy of (Vasomax) in Patients with Erectile dysfnction. Int J Imp Res 1999; 11 (Supple 1): S71. 6 Wyllie M G, Andersson K-E. Oraly Active Agents: The Potential of Alpha-adrenergic Antagonists. In: Carson C, Kirby R, Goldstein, I. eds, Textbook of Erectile Dysfunction. ISIS Medical Media: Oxford 1999; pp. 317± Goldstein I, Lue T, Padma-athan H, Rosen R, Steers W and Wicker P. Oral sildena l in the treatment of erectile dysfunction. ew Engl J Med 1998; 338: 1397± Lal S, et al. Apomorphine-induced penile tumescence in impotent patients- preliminary ndings. Prog europsychopharmacol Biol Psychiatr. 1987; 11: 235± Goldstein I, Payton T, Schechter, P.J. Double-blind, Placebocontrolled Study of Topiglan, a Topical Gel Formulation of 1% Alprostadil for the In-of ce Treatment of Erectile Dysfunction. Int J Imp Res 1999; 11 (Supple 1): S71.
Role of alpha adrenergic receptors in erectile function
(2000) 12, Suppl 1, S48±S63 ß 2000 Macmillan Publishers Ltd. All rights reserved 0955-9930/00 $15.00 www.nature.com/ijir Role of alpha adrenergic receptors in erectile function A Traish 1,2 *, Kim 1, RB
More informationOnset and duration of action of sildena l citrate for the treatment of erectile dysfunction
Onset and duration of action of sildena l citrate for the treatment of erectile dysfunction Ian Eardley, 1 Peter Ellis, 2 Mitradev Boolell 2 & Maria Wulff 2 1 Department of Urology, St James University
More informationMMM. Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS
Dr Tan & Partners MMM Vol. 1 No. 1 Morbidity & Mortality Meeting 14 th November 2014 Introduction Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS Tadalafil 5mg daily is a well established
More informationIC351 (tadalafil, Cialis): update on clinical experience
(2002) 14, Suppl 1, S57 S64 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir IC351 (tadalafil, Cialis): update on clinical experience 1 * 1 Urological practice,
More informationMALE SEXUAL DYSFUNCTION. Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara
MALE SEXUAL DYSFUNCTION Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara DEFINITION The inability to achieve a satisfactory sexual relationship May involve : - inadequacy
More informationfor ED and LUTS/BPH Pierre Sarkis, M.D. Assistant Professor Fellow of the European Board of Urology
Tadalafil 5 mg once daily for ED and LUTS/BPH Pierre Sarkis, M.D. Assistant Professor Fellow of the European Board of Urology Why this conference? Not promotional but educational The pharmacist regularly
More informationCanadian Undergraduate Urology Curriculum (CanUUC): Erectile Dysfunction
Canadian Undergraduate Urology Curriculum (CanUUC): Erectile Dysfunction Last reviewed July 2014 Objectives 1. Define erectile dysfunction 2. List and classify the risk factors for erectile dysfunction
More informationD Udelson, A Nehra, DG Hatzichristou, K Azadzoi, RB Moreland, RJ Krane, I Saenz de Tejada and I Goldstein
International Journal of Impotence Research (1998) 10, 89±99 ß 1998 Stockton Press All rights reserved 0955-9930/98 $12.00 http://www.stockton-press.co.uk/ijir Engineering analysis of penile hemodynamic
More informationManaging the Patient with Erectile Dysfunction: What Would You Do?
Managing the Patient with Erectile Dysfunction: What Would You Do? Florida A & M University College of Pharmacy and Pharmaceutical Sciences 42 nd Annual Clinical Symposium Wayne A. Sampson, M.D. Cross
More informationErectile Dysfunction Medical Treatment
1 Erectile Dysfunction Medical Treatment Alireza Ghoreifi Assistant of Urology Mashhad University of Medical Sciences March 2012 2 Treatment of ED Unknown cases of ED First-line therapy Second-line therapy
More informationIs there a role of radial rigidity in the evaluation of erectile dysfunction?
(2001) 13, 200±204 ß 2001 Nature Publishing Group All rights reserved 0955-9930/01 $15.00 www.nature.com/ijir Is there a role of radial rigidity in the evaluation of erectile dysfunction? JH Ku 1 *, YS
More informationThe effect of sildenafil on electrostimulation-induced erection in the rat model
(2002) 14, 251 255 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir The effect of sildenafil on electrostimulation-induced erection in the rat model N Ueno 1,
More informationManaging Erectile Dysfunction
Managing Erectile Dysfunction Lewis E. Harpster MD, FACS Urology of Central PA 4/23/16 1 Objectives 1. Review physiologic mechanism of erection 2. Discuss medical management of ED 3. Discuss surgical management
More information/02/ /0 Vol. 168, , October 2002 THE JOURNAL OF UROLOGY
0022-5347/02/1684-1332/0 Vol. 168, 1332 1336, October 2002 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2002 by AMERICAN UROLOGICAL ASSOCIATION, INC. DOI: 10.1097/01.ju.0000028041.27703.da Original
More informationReview of intraurethral suppositories and iontophoresis therapy for erectile dysfunction
(2000) 12, Suppl 4, S86±S90 ß 2000 Macmillan Publishers Ltd All rights reserved 0955-9930/00 $15.00 www.nature.com/ijir Review of intraurethral suppositories and iontophoresis therapy for erectile dysfunction
More informationERECTILE DYSFUNCTION DIAGNOSIS
ERECTILE DYSFUNCTION DIAGNOSIS Head of Andrology and Sexual Medicine Dep.of Urology and Nefrology Hospital Virgen del Rocío ANDROMEDI. Sexual Medicine SEVILLA. SPAIN General Secretary ESSM Natalio Cruz
More informationCLINICAL RESEARCH Effects of alpha-2 blockade on sexual response: experimental studies with Delequamine (RS15385)
(2000) 12, Suppl 1, S64±S69 ß 2000 Macmillan Publishers Ltd All rights reserved 0955-9930/00 $15.00 www.nature.com/ijir CLINICAL RESEARCH : experimental studies with Delequamine (RS15385) 1 1 The Kinsey
More informationPriapism. Medical Student case-based learning
Priapism Medical Student case-based learning A 45 year old man presents with an erection lasting over 5 hours. What are the two major subtypes of priapism? Types of Priapism Ischemic veno-occlusive or
More informationDiagnosis and management of sexual dysfunction. Dr Chris Simpson Consultant Psychiatrist
Diagnosis and management of sexual dysfunction Dr Chris Simpson Consultant Psychiatrist What are we talking about? Male Erectile dysfunction Premature ejaculation Delayed ejaculation Sexual aversion Paraphilia
More informationErectile Dysfunction: A Primer for Primary Care Providers
Erectile Dysfunction: A Primer for Primary Care Providers Jeanne Martin, DNP, ANP-BC Objectives 1. Understand the definition, incidence and prevalence of Erectile Dysfunction in the U.S. 2. Understand
More information, David Stultz, MD. Erectile Dysfunction. David Stultz, MD September 10, 2001
Erectile Dysfunction David Stultz, MD September 10, 2001 Case Presentation A 66 year old male presents to your office requesting Viagra. He states that for the past year he has had difficulty forming
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 199, by the Massachusetts Medical Society VOLUME 33 M AY 14, 199 NUMBER ORAL IN THE TREATMENT OF ERECTILE DYSFUNCTION IRWIN GOLDSTEIN, M.D., TOM F. LUE, M.D.,
More informationTopical application of a Rho-kinase inhibitor in rats causes penile erection
(2004) 16, 294 298 & 2004 Nature Publishing Group All rights reserved 0955-9930/04 $30.00 www.nature.com/ijir Topical application of a Rho-kinase inhibitor in rats causes penile erection Y Dai 1,2,3, K
More informationThe Impact of Mental Illness on Sexual Dysfunction
Balon R (ed): Sexual Dysfunction. The Brain-Body Connection. Adv Psychosom Med. Basel, Karger, 2008, vol 29, pp 89 106 The Impact of Mental Illness on Sexual Dysfunction Zvi Zemishlany Abraham Weizman
More informationAbout Erectile Dysfunction. Causes, self-test and treatment
About Erectile Dysfunction Causes, self-test and treatment 2015 One Way S.r.l. All rights reserved. Gift copy for physicians. Illustrated by Davide Ceccon With an unrestricted grant from Recordati About
More informationLow Energy Shockwaves for the Treatment of Erectile Dysfunction Y. Vardi, B. Appel, I Gruenwald
Low Energy Shockwaves for the Treatment of Erectile Dysfunction Y. Vardi, B. Appel, I Gruenwald Neuro-Urology Unit, Rambam Medical Center & the Technion Faculty of Medicine Haifa, Israel 3 crucial questions
More informationImmediate penile prosthesis insertion after failed T shunt and snake maneuver in patient with prolonged priapism
Immediate penile prosthesis insertion after failed T shunt and snake maneuver in patient with prolonged priapism Evangelos Zacharakis PhD, FRCS, FECSM, FEAA Consultant Urological Surgeon St Peter s Anrology
More informationA Proposed Study of Hyperbaric Oxygen Therapy Following Radical Prostatectomy: Effects on Erectile Dysfunction
A Proposed Study of Hyperbaric Oxygen Therapy Following Radical Prostatectomy: Effects on Erectile Dysfunction Anthony J. Bella MD, FRCSC Division of Urology, Department of Surgery and Department of Neuroscience
More informationDefined as the consistent inability to attain and maintain an erection adequate for sexual intercourse Usually qualified by being present for several
Defined as the consistent inability to attain and maintain an erection adequate for sexual intercourse Usually qualified by being present for several months and occurring at least half the time. Vinik
More informationSevere erectile dysfunction is a marker for hyperprolactinemia
(2001) 13, 176±182 ß 2001 Nature Publishing Group All rights reserved 0955-9930/01 $15.00 www.nature.com/ijir Severe erectile dysfunction is a marker for hyperprolactinemia AM Johri 1, JPW Heaton 1 * and
More informationSponsored by. Schering. Sidney Glina
Sponsored by Schering Sidney Glina Testosterone and erectile dysfunction Sidney Glina Keywords Androgen Hormone replacement therapy Hypogonadism Impotence Testosterone Abstract The role of testosterone
More informationThe anocavernosal erectile dysfunction syndrome II Anal ssure and erectile dysfunction
(2000) 12, 279±283 ß 2000 Macmillan Publishers Ltd All rights reserved 0955-9930/00 $15.00 www.nature.com/ijir The anocavernosal erectile dysfunction syndrome II Anal ssure and erectile dysfunction A Sha
More informationDifferent hemodynamic responses by color Doppler ultrasonography studies between sildenafil non-responders and responders
DOI: 10.1111/j.1745-7262.2007.00227.x www.asiaandro.com. Clinical Experience. Different hemodynamic responses by color Doppler ultrasonography studies between sildenafil non-responders and responders Shih-Tsung
More informationA dose-response study of alprostadil sterile powder (S.Po.) (Caverject # ) for the treatment of erectile dysfunction in Korean and Indonesian men
International Journal of Impotence Research (1997) 9, 47±51 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 A dose-response study of alprostadil sterile powder (S.Po.) (Caverject # ) for
More informationTestosterone and PDE5 inhibitors in the aging male
Testosterone and PDE5 inhibitors in the aging male Francesco Romanelli Department of Experimental Medicine Medical Pathophysiology, Food Science and Endocrinology Section Sapienza University of Rome 3005
More informationUp to 85 Percent of Men Achieved Significantly Improved Erections
Corporate Investor Relations First Release of Vardenafil Phase III Pivotal Study Data: Up to 85 Percent of Men Achieved Significantly Improved Erections Additional Phase III Data Show Significant Improvement
More informationGUIDELINES ON ERECTILE DYSFUNCTION
16 GUIDELINES ON ERECTILE DYSFUNCTION E. Wespes (chairman), E. Amar, D. Hatzichristou, Dr. F. Montorsi, J. Pryor, Y. Vardi Eur Urol 2002;41:1-5 1. Background, definition and classification Male erectile
More informationIntroduction. D Sandhu 1, E Curless 2, J Dean 3, G Hackett 4, S Liu 5, D Savage 6, R Oakes 7 * and G Frentz 8
International Journal of Impotence Research (1999) 11, 91±97 ß 1999 Stockton Press All rights reserved 0955-9930/99 $12.00 http://www.stockton-press.co.uk/ijir A double blind, placebo controlled study
More informationThe range of therapies for treating erectile dysfunction
REVIEW CME ARTICLE ORAL PHARMACOTHERAPY FOR ERECTILE DYSFUNCTION: CURRENT PERSPECTIVES ARTHUR L. BURNETT Dr. Burnett is on the Speakers Bureau for Pfizer. From the Department of Urology, Johns Hopkins
More informationClinical Trial Study Synopsis
Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency
More informationTadalafil: a novel treatment for erectile dysfunction
European Heart Journal Supplements (22) 4 (Supplement H), H24 H31 Tadalafil: a novel treatment for erectile dysfunction F. Giuliano 1 and L. Varanese 2 1 Department of Urology, AP-HP, Centre Hospitalier
More information2401 : Anatomy/Physiology
Dr. Chris Doumen Week 11 2401 : Anatomy/Physiology Autonomic Nervous System TextBook Readings Pages 533 through 552 Make use of the figures in your textbook ; a picture is worth a thousand words! Work
More informationGUIDELINES ON ERECTILE DYSFUNCTION
GUIDELINES ON ERECTILE DYSFUNCTION (Text updated March 2005) E. Wespes (chairman), E. Amar, D. Hatzichristou, K. Hatzimouratidis, F. Montorsi, J. Pryor, Y. Vardi 88 Erectile Dysfunction Eur Urol 2001;40:97-101
More informationSexual dysfunction in men with diabetes
Article Sexual dysfunction in men with diabetes Lesley Mills Citation: Mills L (2015) Sexual dysfunction in men with diabetes. Journal of Diabetes Nursing 19: 332 8 Article points 1. Sexual dysfunction
More informationErectile dysfunction. By Anas Hindawi Supervised by Dr Khalid AL Sayyid
Erectile dysfunction By Anas Hindawi Supervised by Dr Khalid AL Sayyid ED is the persistent/recurrent inability to attain and/or maintain a penile erection rigid enough for satisfactory sexual intercourse
More information/04/ /0 Reprinted from Vol. 172, , August 2004 THE JOURNAL OF UROLOGY
0022-5347/04/1722-0658/0 Reprinted from Vol. 172, 658 663, August 2004 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2004 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000132389.97804.d7
More informationInternational Index of Erectile Function Questionnaire IIEF
International Index of Erectile Function Questionnaire IIEF Instructions: These questions ask about the effects your erections have had on your sex life, over the past 4 weeks. Please answer the following
More informationGanglionic Blockers. Ganglion- blocking agents competitively block the action of
Ganglionic Blockers Ganglion- blocking agents competitively block the action of acetylcholine and similar agonists at nicotinic (Nn) receptors of both parasympathetic and sympathetic autonomic ganglia.
More informationERECTILE DYSFUNCTION (ED) is the persistent
Transplantation Treatment of Erectile Dysfunction With Sildenafil Citrate in Renal Allograft Recipients: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial Raj K. Sharma, FASN, Narayan Prasad,
More informationOpinion: Yes. PDE-5 inhibitors should be used post radical prostatectomy as erection function rehabilitation?
Difference of opinion Vol. 43 (3): 385-389, May - June, 2017 doi: 10.1590/S1677-5538.IBJU.2017.03.03 PDE-5 inhibitors should be used post radical prostatectomy as erection function rehabilitation? Opinion:
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
Public Disclosure Synopsis Protocol A7772 September 25 Final PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
More informationEvidence Review for Surrey Prescribing Clinical Network. Treatment: Oral and non-oral combination therapy for erectile dysfunction
Evidence Review for Surrey Prescribing Clinical Network Treatment: Oral and non-oral combination therapy for erectile dysfunction Prepared by: Linda Honey Topic Submitted by: Prescribing Clinical Network
More informationERECTION MISDIRECTION: PENILE REHABILITATION & TREATMENTS FOR ERECTILE DYSFUNCTION. Gregory Harochaw Pharmacy Manager Tache Pharmacy (204)
ERECTION MISDIRECTION: PENILE REHABILITATION & TREATMENTS FOR ERECTILE DYSFUNCTION Gregory Harochaw Pharmacy Manager Tache Pharmacy (204) 233-3469 Nerve Function After careful prostatectomy where the erectile
More informationSmooth muscle pathology and erectile dysfunction
(2002) 14, Suppl 1, S17 S21 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir and erectile dysfunction 1 * 1 Department of Urology, C.H.U. de Charleroi, Charleroi,
More informationnumber Done by Corrected by Doctor Alia Shatnawi
number 11 Done by Lojayn Salah Corrected by Doctor Alia Shatnawi The last thing we talked about in the previous lecture was the effect of a drug at a particular dose, and we took this equation: E= Emax
More informationaviptadil / phentolamine 25 micrograms / 2mg solution for injection (Invicorp ) SMC No 1284/17 Evolan Pharma AB
aviptadil / phentolamine 25 micrograms / 2mg solution for injection (Invicorp ) SMC No 1284/17 Evolan Pharma AB 10 November 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of
More informationPsychopharmacological Treatment of Sexual Dysfunction. American Society Clinical Psychopharmacology
Psychopharmacological Treatment of Sexual Dysfunction American Society Clinical Psychopharmacology 2005 Teaching Points 1. Sexual dysfunction is highly prevalent in the general population 2. Sexual dysfunction
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationLong-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis
(2003) 15, 318 322 & 2003 Nature Publishing Group All rights reserved 0955-9930/03 $25.00 www.nature.com/ijir Long-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction
More informationASSESSMENT OF PREMATURE EJACULATION AND ERECTILE DYSFUNCTION
ASSESSMENT OF PREMATURE EJACULATION AND ERECTILE DYSFUNCTION Dr Michael Gillman St Andrews Hospital Wickham Terrace Spring Hill Mater Private Clinic, South Brisbane Shore St West Medical Centre, Cleveland
More informationGUIDELINES ON PRIAPISM
GUIDELINES ON PRIAPISM (Text update March 2015) A. Salonia, I. Eardley, F. Giuliano, I. Moncada, K. Hatzimouratidis Eur Urol 2014 Feb;65(2):480-9 Introduction Priapism is a pathological condition representing
More informationIntroduction. H Porst
International Journal of Impotence Research (1997) 9, 187±192 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 (medicated urethral system for erection) vs intracavernous AlprostadilÐa comparative
More informationPhysiology and disturbances of sexual functions Prof. Jolanta Słowikowska-Hilczer, M.D., Ph.D.
Physiology and disturbances of sexual functions Prof. Jolanta Słowikowska-Hilczer, M.D., Ph.D. Department of Andrology and Reproductive Endocrinology Medical University of Łódź, Poland SEXUALITY Sexuality
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE. Bulletin 169: Daily Tadalafil (Cialis ) for penile rehabilitation following radical prostactectomy
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE September 2012 Review date: September 2014 Bulletin 169: Daily Tadalafil (Cialis ) for penile rehabilitation following radical prostactectomy JPC Recommendation:
More informationMeasurement of erectile dysfunction in population-based studies: the use of a single question self-assessment in the Massachusetts Male Aging Study
(2000) 12, 197±204 ß 2000 Macmillan Publishers Ltd All rights reserved 0955-9930/00 $15.00 www.nature.com/ijir Measurement of erectile dysfunction in population-based studies: the use of a single question
More informationSelect Prostaglandins
Select Prostaglandins Epoprostenol Sodium (Prostacyclin) Alprostadil (Caverject, Muse) Epoprostenol Sodium (Prostacyclin) Alprostadil (Caverject, Muse) Promoted in conjunction with Pharmaceutical Materials
More informationDisclosure Slide. Dr Michael Gillman IMPOTENCE ERECTILE DIFFICULTIES. Do Men Really Care??? 15/10/2014 ASSESSMENT OF ERECTILE DYSFUNCTION
ASSESSMENT OF ERECTILE DYSFUNCTION Dr Michael Gillman St Andrews Hospital North St Specialist Suites Mater Hospital 3 rd Floor Mater Private Clinic Wesley Hospital Suite 5 Level 9 Evan Thomson Bld Cleveland-
More informationPhosphodiesterase Type 5 Inhibitors Quantity Limit Program Summary
Phosphodiesterase Type 5 Inhibitors Quantity Limit Program Summary FDA APPROVED INDICATIONS AND DOSAGE 1-4,23 Agent FDA Approved Dosage and Administration Indication Cialis (tadalafil) (ED) ED; As needed:
More informationIntracavernous administration of SIN-1 þ VIP in an in vivo rabbit model for erectile function
(2002) 14, 44 49 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir Intracavernous administration of SIN-1 þ VIP in an in vivo rabbit model for erectile function
More informationIs there a role for extracorporeal shock wave therapy for erectile dysfunction unresponsive to phosphodiesterase type 5 inhibitors?
DOI 10.1007/s00345-016-1899-y LETTER TO THE EDITOR Is there a role for extracorporeal shock wave therapy for erectile dysfunction unresponsive to phosphodiesterase type 5 inhibitors? Zi jun Zou 1 Zhi hong
More informationIntroduction. CG McMahon 1 * and K Touma 1
Predictive value of patient history and correlation of nocturnal penile tumescence, colour duplex Doppler ultrasonography and dynamic cavernosometry and cavernosography in the evaluation of erectile dysfunction
More informationDrug Receptor Interactions and Pharmacodynamics
Drug Receptor Interactions and Pharmacodynamics Dr. Raz Mohammed MSc Pharmacology School of Pharmacy 22.10.2017 Lec 6 Pharmacodynamics definition Pharmacodynamics describes the actions of a drug on the
More informationSildenafil Citrate (VIAGRA ) Improves Erectile Function in Elderly Patients With Erectile Dysfunction: A Subgroup Analysis
Journal of Gerontology: MEDICAL SCIENCES 2001, Vol. 56A, No. 2, M113 M119 Copyright 2001 by The Gerontological Society of America Sildenafil Citrate (VIAGRA ) Improves Erectile Function in Elderly Patients
More informationPharmacology - Problem Drill 11: Vasoactive Agents
Pharmacology - Problem Drill 11: Vasoactive Agents Question No. 1 of 10 1. Vascular smooth muscle contraction is triggered by a rise in. Question #01 (A) Luminal calcium (B) Extracellular calcium (C) Intracellular
More informationMedicines Q&As. Date prepared: November 2016
Q&A 128.3 What is the rationale and evidence for the use of phosphodiesterase-5 inhibitors as supportive therapy to rehabilitate Erectile Function after nerve sparing radical prostatectomy? Summary Prepared
More informationWill Medical Management of Benign Prostatic Hyperplasia Result in Better or Worse Sexual Function in Men?
Urol Sci 2011;22(1):14 18 MINI REVIEW Will Medical Management of Benign Prostatic Hyperplasia Result in Better or Worse Sexual Function in Men? Thomas I.S. Hwang 1,2,3 * 1 Shin Kong WHS Hospital, Taipei,
More informationShockwave Therapy Applications
Shockwave Pressure Level (bar) Shockwave Therapy Applications 500 Urology 250 0 ESWL ~ 450 Bar Stone Fragmentation ESWT ~ 200 bar Anti Inflammatory Orthopedics LSWT ~80 bar Angiogenesis ED 80 s 90 s 2000+
More informationBJUI. Study Type Diagnostic (case series) Level of Evidence 4 OBJECTIVE CONCLUSIONS
2008 The Authors. Journal compilation 2008 BJU International Sexual Medicine PARK et al. BJUI BJU INTERNATIONAL Why a combined intracavernosal injection with trimix and oral sildenafil is reliable therapy
More informationIan Eardley Department of Urology, Leeds Teaching Hospital Trust
Ian Eardley Department of Urology, Leeds Teaching Hospital Trust Assessment of the man with ED Medical therapy for man with ED What to do when pills fail Sexual stimulus Neural pathways Neurotransmitter
More informationERECTILE DYSFUNCTION. & Current Therapies. GP Conference, Rotorua 7-10 June 2012
ERECTILE DYSFUNCTION & Current Therapies GP Conference, Rotorua 7-10 June 2012 Jan Burns & Annie Woodsford Jan: EN, RCpN, BHSc, RPN (USA),MHSc, Member of the Sexual Medicine Society Urology Nurse Specialist
More informationINTRACAVERNOSAL INJECTION OF PHARMACOLOGICAL AGENTS IN THE DIAGNOSIS AND TREATMENT OF IMPOTENCE
INTRACAVERNOSAL INJECTION OF PHARMACOLOGICAL AGENTS IN THE DIAGNOSIS AND TREATMENT OF IMPOTENCE Abstract Pages with reference to book, From 172 To 176 Qaisar H Siraj ( Armed Forces Institute of Pathology,
More informationAbstract. Introduction. Vascular and cavernosal smooth muscle in the penis
RBMOnline - Vol 7. No 4. 456 461 Reproductive BioMedicine Online; www.rbmonline.com/article/994 on web 9 October 2003 Article Novel PDE5 inhibitors for the treatment of male erectile dysfunction Jas Kalsi
More informationClinic for urology, pediatric urology and andrology. Penile diseases. Dr. Arne Hauptmann
Clinic for urology, pediatric urology and andrology JUSTUS- LIEBIG UNVERISTY GIESSEN Penile diseases Dr. Arne Hauptmann Clinic for urology, pediatric urology and andrology University Giessen und Marburg
More informationAssessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation
(2001) 13, 41±45 ß 2001 Nature Publishing Group All rights reserved 0955-9930/01 $15.00 www.nature.com/ijir Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation
More informationREVIEW The relationship between hypogonadism and erectile dysfunction
(2008) 20, 231 235 & 2008 Nature Publishing Group All rights reserved 0955-9930/08 $30.00 www.nature.com/ijir REVIEW The relationship between hypogonadism and erectile dysfunction TIS Hwang 1,2,3 and Y-C
More informationDaily vs. on-demand PDE-5 inhibitors for management of erectile dysfunction following treatment for prostate cancer
Daily vs. on-demand PDE-5 inhibitors for management of erectile dysfunction following treatment for prostate cancer Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) February 2018
More informationThe use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction
(2002) 14, 245 250 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic
More informationReview Article Penile Rehabilitation Therapy with PDE-V Inhibitors Following Radical Prostatectomy: Proceed with Caution
Advances in Urology Volume 2009, Article ID 852437, 4 pages doi:10.1155/2009/852437 Review Article Penile Rehabilitation Therapy with PDE-V Inhibitors Following Radical Prostatectomy: Proceed with Caution
More informationDATE BIO# NAME: Last First Middle REFERRING PHYSICIAN NAME: REFERRING PHYSICIAN SPECIALTY (Urologist, Internist, etc.): PRIMARY CARE PHYSICIAN NAME:
DATE BIO# ERECTILE DYSFUNCTION QUESTIONNAIRE NAME: Last First Middle BIRTHDATE: OCCUPATION: REFERRING PHYSICIAN NAME: REFERRING PHYSICIAN SPECIALTY (Urologist, Internist, etc.): PRIMARY CARE PHYSICIAN
More informationEFFICACY OF TADALAFIL FOR THE TREATMENT OF ERECTILE DYSFUNCTION AT 24 AND 36 HOURS AFTER DOSING: A RANDOMIZED CONTROLLED TRIAL
ADULT UROLOGY EFFICACY OF TADALAFIL FOR THE TREATMENT OF ERECTILE DYSFUNCTION AT 24 AND 36 HOURS AFTER DOSING: A RANDOMIZED CONTROLLED TRIAL HARTMUT PORST, HARIN PADMA-NATHAN, FRANÇOIS GIULIANO, GREG ANGLIN,
More informationI N T I M A C Y A N D S E X U A L I T Y I N L A T E R L I F E
I N T I M A C Y A N D S E X U A L I T Y I N L A T E R L I F E 2 0 1 6 DESPITE THE COMMON COMPLAINT, EACH PATIENT COMES AS AN INDIVIDUAL, WITH UNIQUE EXPECTATIONS My special interest Counseling patients
More informationMANAGEMENT UPDATE , LLC MedReviews
MANAGEMENT UPDATE 2013 MedReviews, LLC rostate cancer is the most common cancer in men over the age of 50 years. 1 When patients undergo a radical prostatectomy (RP), there is a risk of postoperative erectile
More informationLONG-TERM EFFECT OF SILDENAFIL CITRATE ON ERECTILE DYSFUNCTION AFTER RADICAL PROSTATECTOMY: 3-YEAR FOLLOW-UP
ADULT UROLOGY LONG-TERM EFFECT OF SILDENAFIL CITRATE ON ERECTILE DYSFUNCTION AFTER RADICAL PROSTATECTOMY: 3-YEAR FOLLOW-UP RUPESH RAINA, MILTON M. LAKIN, ASHOK AGARWAL, RAKESH SHARMA, KUSH K. GOYAL, DROGO
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT VIAGRA 25 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 25 mg sildenafil as citrate.
More informationIf you have questions or want more information on VIAGRA, talk to your doctor, visit or call viagra ( ).
You ve been prescribed VIAGRA to treat erectile dysfunction (ED). Below is some important information to help you get the most out of VIAGRA. VIAGRA works by increasing blood flow to the penis, which helps
More informationERECTION HARDNESS: A UNIFYING FACTOR FOR DEFINING RESPONSE IN THE TREATMENT OF ERECTILE DYSFUNCTION
ERECTION HARDNESS: A UNIFYING FACTOR FOR DEFINING RESPONSE IN THE TREATMENT OF ERECTILE DYSFUNCTION JOHN P. MULHALL, LAURENCE A. LEVINE, and KLAUS-PETER JÜNEMANN ABSTRACT The extensive sildenafil citrate
More informationBasics of Pharmacology
Basics of Pharmacology Pekka Rauhala Transmed 2013 What is pharmacology? Pharmacology may be defined as the study of the effects of drugs on the function of living systems Pharmacodynamics The mechanism(s)
More informationErectile Dysfunction (ED) Shawn McGee M.D. CentraCare Adult and Pediatric Urology January 30 th, 2016
Erectile Dysfunction (ED) Shawn McGee M.D. CentraCare Adult and Pediatric Urology January 30 th, 2016 Erectile dysfunction: The inability to attain or maintain penile erection sufficient for satisfactory
More informationInitial experience with linear focused shockwave treatment for erectile dysfunction: a 6-month follow-up pilot study
International Journal of Impotence Research (2014), 1 5 2014 Macmillan Publishers Limited All rights reserved 0955-9930/14 www.nature.com/ijir ORIGINAL ARTICLE Initial experience with linear focused shockwave
More informationNitric Oxide in the Penis: Scientific Discoveries and Clinical Applications
Nitric Oxide in the Penis: Scientific Discoveries and Clinical Applications Arthur L. (Bud) Burnett, M.D., M.B.A., F.A.C.S. Patrick C. Walsh Professor of Urology The James Buchanan Brady Urological Institute
More information